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Abstract 
Computational approaches are increasingly utilised in development of bio-enabling formulations, 
including self-emulsifying drug delivery systems (SEDDS), facilitating early indicators of success. This 
study investigated if in silico predictions of drug solubility gain i.e. solubility ratios (SR), after 
dispersion of a SEDDS in biorelevant media could be predicted from drug properties. Apparent 
solubility upon dispersion of two SEDDS in FaSSIF was measured for 30 structurally diverse poorly 
water soluble drugs. Increased drug solubility upon SEDDS dispersion was observed in all cases, with 
higher SRs observed for cationic and neutral versus anionic drugs at pH 6.5. Molecular descriptors 
and solid-state properties were used as inputs during partial least squares (PLS) modelling resulting 
in predictive models for SRMC (r2 = 0.81) and SRLC (r2 = 0.77). Multiple linear regression (MLR) 
facilitated generation of simplified SR equations with high predictivity (SRMC r2 = 0.74; SRLC r2 = 0.69), 
requiring only three drug properties; partition coefficient at pH 6.5 (logD6.5), melting point (Tm) and 
aromatic bonds as fraction of total bonds (FArom_B). Through using the equations to inform drug 
developability classifications (DCS) for drugs that have already been licensed as lipid based 








PWSD, Poorly Water-Soluble Drug; LBF, Lipid-Based Formulations; SEDDS, Self-emulsifying drug 
delivery systems; GIT, Gastrointestinal tract; O/W, oil-in-water; DCS, Developability Classification 
System; DCS, Developability Classification System; rDCS, Refined Developability Classification 
System; An Absorption Number; Do, Dose Number; BCS, Biopharmaceutics Classification System; 







   
 
   
 
Introduction  
Increasing numbers of poorly water soluble drugs (PWSD) in development pipelines has intensified 
the need for bio-enabling formulations to enhance oral bioavailability (1, 2). One such approach 
involves administration of drug substances in Lipid-Based Formulations (LBFs), which enhance 
apparent solubility of PWSDs, while potentially also increasing absorption via stimulation of 
endogenous lipid absorption pathways for lipophilic xenobiotics. Despite numerous commercial 
examples of LBFs, with previous estimations of up to 4% of orally administered drug products utilising 
LBFs (3), it was recently observed that relative numbers of new commercial products using LBFs 
have declined over the last decade (4). Such statistics suggest challenges to more widespread 
adoption of LBFs among pharmaceutical companies, potentially linked to a lack of clear guidance on 
appropriate early screening to guide bio-enabling formulation selection (5).  
Self-emulsifying drug delivery systems (SEDDS) fall under the umbrella term LBFs, and refer to 
combinations of oils with surfactants and co-solvents which spontaneously emulsify forming a stable 
emulsion on dispersion in the gastrointestinal tract (GIT) (6). Ability to self-emulsify and maintain 
solubilisation on dispersion is a key SEDDS performance determinant. Typically, the drug dose 
should be soluble in the SEDDS vehicle, and much effort is focused on determining the inherent lipid 
solubility of the drug, usually involving resource intensive drug solubility screening in a range of lipid 
excipients (7, 8). More recently, the application of computational models, in conjunction with drug 
biopharmaceutical profiling, has been explored to support higher throughput formulation selection for 
LBFs (9, 10). While certain computational approaches aim to determine drug properties which 
produce favourable oral drug candidates, other tools have instead examined molecular properties that 
may signal necessity for use of bio-enabling strategies or alternatively signal greater suitability for a 
particular type of bio-enabling strategy. Regarding the latter, a number of noteworthy studies have 
demonstrated utility of computational pharmaceutics approaches to predict lipid solubility to act as a 
guide for maximal dose loading in LBF pre-concentrates (11-14). Critically, while predictions of the 
drug solubility in lipids are useful to guide initial understanding of the maximum dose loading in the 
SEDDS vehicle, this approach does not represent the sole criterion for LBF suitability.  
Modifications in the GIT upon SEDDS ingestion are crucial in determining formulation performance, 
as solubilisation capacity in luminal media can be altered dramatically following SEDDS emulsification 
and through interactions of lipid excipients with endogenous solubilising species (15-17). SEDDS 
dispersion leads to increased drug solubilisation, transient supersaturation, and potentially 
precipitation, thereby presenting drugs to intestinal fluids at concentrations exceeding their equilibrium 
solubility (18). From a biopharmaceutical perspective, apparent drug solubility in intestinal fluid upon 
SEDDS dispersion appears critical in determining LBF suitability. Accordingly, the lipid formulation-
performance classification system emphasises formulation capability to retain solubilisation upon 
dispersion and digestion (19). The use of simulated biorelevant fluids in such in vitro assessments is 
likely to be a more reliable indicator of whether a SEDDS approach can effectively solubilise the dose 
in vivo. Biorelevant testing is an integral part of pharmaceutical characterisation, revealing 
concentrations likely to be soluble within human intestinal fluids (HIF) (20, 21), while a key tenet of the 
   
 
   
 
Developability Classification System (DCS) is the use of biorelevant solubility in fasted state simulated 
intestinal fluids (FaSSIF) as an improved guide to in vivo performance and drug developability (22). 
More recently, a refined DCS (rDCS) extended this developability concept to include customised in 
vitro assessments of supersaturation and precipitation risks involving Absorption Number (An) and 
Dose Number (Do) (23). Such developability guides, along with decision trees utilising biorelevant 
media instead of buffered aqueous media (22, 24-26), signify emerging emphasis on developability 
and biopharmaceutical concepts in early product testing. However, as in vitro techniques utilised to 
predict the dose that is effectively solubilised in vivo can be complex and resource heavy, 
development of models capable of predicting this dose are strongly merited (27). 
With regard to both advancing LBF computational pharmaceutics and use of biopharmaceutically 
relevant conditions, our hypothesis was to apply a computational approach to predict solubility 
increases upon SEDDS dispersion. Given the inherent complexity of the mixed colloidal species 
formed upon dispersion of SEDDS with endogenous biliary lipids, approaches to predict apparent 
solubility are considered complex at this stage. As an alternative, the solubility increase achieved via 
SEDDS dispersion in FaSSIF, relative to drug solubility in FaSSIF, represents a more realistic 
modelling parameter. This can be used to inform the maximal dose solubilised within the intestine, 
assuming experimental drug solubility in FaSSIF is known. Accordingly, this study attempted to apply 
a computational approach in relating drug properties to predict solubility increases (i.e. solubility 
ratios) following SEDDS dispersion. This approach can therefore be used to effectively guide the dose 
number (Do) produced in intestinal fluids. Subsequently, this study explored suitability of linking the 
predicted Do to the framework provided by the DCS and hence, providing a tool for guiding 
developability of a SEDDS formulation strategy in early stage drug development. To achieve this aim, 
apparent drug solubility of 30 PWSD was experimentally determined upon dispersion in FaSSIF of 
two prototype SEDDS. SEDDS were selected based on prior ability to spontaneously emulsifying, 
forming a stable microemulsion and were composed of either a medium chain (SEDDSMigylol812) or 
long chain (SEDDSOliveOil) oil phase, with a common surfactant, co-surfactant blend in order to 
examine their excipient effects (27). Solubility ratios (SRMC and SRLC) achieved versus FaSSIF 
solubility were collated with drug descriptors to develop computational models and predictive 
equations. Through prediction of DCS classifications, this work aimed to advance the concept of 
computational pharmaceutics to inform drug developability, exemplifying use of predictive tools to 
expedite formulation options in early development. 
 
Methods 
Dataset Selection  
A dataset of 30 structurally diverse PWSD was selected (Table 1). Drugs were selected based on a 
range of criteria including availability of published reports of drug properties, utilisation in previous 
LBF computational modelling publications and drugs commercially licensed as LBFs (11, 12, 25, 28). 
Light absorbing ability of the compounds’ UV-chromophores were also considered, to allow sufficient 
detectability by the fibre optic UV probes of the µDISS Profiler. A final drug data set was selected to 
   
 
   
 
ensure a sufficient representation of drugs categorised as anionic (8), cationic (9) and neutral (13) 
overall at pH 6.5. The Henderson-Hasselbalch equation was used to determine ionisation at pH 6.5 
(Table 1). All drug compounds were purchased from Kemprotec Ltd (Cumbria, United Kingdom). The 
final dataset displayed a wide physiochemical profile of molecular weight (MW) (230-868.44 g/mol), 
lipophilicity (clogP) (2.1-7.1) and melting point (Tm) (79-296.5ºC). 
Formulations 
Two SEDDS previously utilised for oral delivery of a model PWSD in preclinical studies were chosen 
(27). SEDDSMigylol812 contained 40% w/w medium chain triglycerides (Miglyol 812) with 20% w/w 
surfactant (Kolliphor RH 40 - polyoxyl-40-hydrogenated castor oil) and 40% w/w co-surfactant (Tween 
85 - polyoxyethylene-(20)–polysorbitan trioleate). SEDDSOliveOil contained 40% w/w long chain 
triglycerides (olive oil), while quantities of surfactant and co-surfactant remained similar to 
SEDDSMigylol812, with 20% Kolliphor RH 40 and 40% Tween 85. Migylol 812N is primarily composed of 
C8 and C10 fatty acids (approx. 60:40%). Olive oil contains saturated and unsaturated fatty acids of 
primarily C16-C18 chain length. Miglyol 812N was kindly gifted from IOI Oleo GmbH (Hamburg, 
Germany), while Olive Oil, Tween 85 and Kolliphor RH 40 were purchased from Sigma-Aldrich 
(Ireland). SEDDS were prepared by weighing exact excipient quantities into a screw cap glass tube 
and incubated at 37 °C, overnight on a stirring plate 200 rpm (Mixdrive 15, 2MAG, Germany).  
Media Preparation 
Phosphate buffer (PhBpH6.5) and FaSSIF-V1 were prepared according to biorelevant.com (Croydon, 
UK) protocol and adjusted to pH 6.5 using a Model 3510 pH/mV/Temperature Meter (Jenway, UK). 
FaSSIF-V1 was chosen due to high correlation with HIF and availability of drug solubility datasets (29, 
30). Water was obtained from a MilliQ water system. All chemicals and solvents were of analytical or 
high-performance liquid chromatography (HPLC) grade and purchased from Sigma-Aldrich (Ireland). 
Conditions for simulating dispersion of the SEDDS in intestinal fluids were produced by dispersing 
SEDDS (1:200 dilution) in PhBpH6.5 (i.e. PhB pH6.5-SEDDSMigylol812 and PhB pH6.5-SEDDSOliveOil) and 
FaSSIF (i.e. FaSSIF-SEDDSMigylol812 and FaSSIF-SEDDSOliveOil). This lipid dilution was chosen to be 
typical of reasonable lipid concentrations found in a biorelevant volume.   
Media Characterisation: Media Droplet Size and Zeta Potential 
Droplet size (nm) and polydispersity index (PDI) of FaSSIF, FaSSIF-SEDDSMigylol812, FaSSIF-
SEDDSOliveOil, PhB pH6.5-SEDDSMigylol812 and PhB pH6.5-SEDDSOliveOil were measured using Dynamic 
Light Scattering (DLS) with a Malvern Zetasizer Nano ZS (Malvern Analytical, US) with a 4mW 633nm 
He-He laser at 37°C with a backscattering angle of 173° using the Stokes-Einstein equation. 
Measurements were performed with unfiltered samples in disposable UV-cuvettes from Sarstedt AG 
& Co. KG (Numbrecht, Germany) (10 x 4 x 45 mm). Refractive indices used were 1.1333 (PhBpH6.5) 
and 1.334 (FaSSIF) (31). The electrophoretic mobility i.e. ζ-potential, of colloidal structures in the 
media was measured using the Zetasizer in disposable folded capillary cells (DTS1070) using the 
Helmholtz-Smoluchowski equation (32). Each analysis was conducted in triplicate, presented as 
mean ± standard deviation.   
   
 
   
 
Experimental Solubility Determination 
Apparent drug solubility studies in FaSSIF, FaSSIF-SEDDSMigylol812 and FaSSIF-SEDDSOliveOil were 
experimentally determined over 24 hours as the 24 hour time point was used for solubility ratios. 
Solubility was determined via either shake flask with RP-HPLC/UV analysis (6 drugs) or µDISS 
Profiler (Pion INC, Woburn, MA) (24 drugs), where preliminary studies verified method comparability 
(Supplementary Materials).  
Shake Flask Method 
Drug was added in excess to triplicate glass vials containing either FaSSIF, FaSSIF-SEDDSMigylol812 
or FaSSIF-SEDDSOliveOil (n=3). pH was maintained at 6.5 prior to experiments. Vials were placed on a 
stirring plate (Mixdrive 15, 2MAG, Germany) in a 37°C incubator at 300 rpm. 300 µl samples were 
removed at 2, 4, 6 and 24 hours. Excess solid was separated using a centrifuge for 15 minutes at 
21,380 x g (Mikro 200 R, Andreas Hettich GmbH & Co. KG, Germany). Samples were diluted in 
acetonitrile for analysis via RP-HPLC/UV. Drug Detection was conducted using an Agilent 1200 series 
HPLC system. The columns and mobile phases used for each drug analysed along with injection 
volume, flowrate and detection wavelength can be found in supplementary materials.  
µDISS Profiler 
Apparent drug solubility (n = 3) was determined at a stirring rate of 300 rpm over 24 hours (37°C). 
Path length of the in situ UV probes was varied (1 - 5 mm) depending on anticipated concentration 
range and the UV absorbance properties of the drug molecule. Standard spectra were collected for 
each compound at pH 6.5 and a linear relationship (r2 > 0.99) was established between absorbance 
and concentration in each case. The experimental run was performed in six vials where a large 
excess of API was added (10-20 times more than the anticipated FaSSIF solubility) to account for the 
potentially large solubility enhancement. These vials contained 15 ml FaSSIF-SEDDSMigylol812 or 
FaSSIF-SEDDSOliveOil and a cross-bar magnetic stirrer. Two additional channels were used as blanks 
to consolidate for potential issues with background changing FaSSIF UV absorbance over time. The 
in situ UV probes scanned the samples at predefined time intervals (30 minutes). Concentrations 
were determined by considering area-under-the-curve (AUC) in second derivative spectra, to lessen 
interference from background turbidity. A range of wavelengths were utilised to quantify drug. Data 
was interpreted using the Au Pro software (Version 5, Pion INC, MA, USA).  
Drug Physiochemical and Molecular Properties 
In excess of 250 descriptors including physiochemical and modelling descriptors were obtained from 
ADMET Predictor 9.5 (Simulations Plus, USA). Tm was obtained from literature (11, 24, 28). 
Biorelevant solubility values in FaSSIF, FeSSIF and PhBpH6.5 were obtained from literature sources 
where available (28, 33). In absence of published data, predicted solubility values were generated 
(ADMET Predictor, Ver. 9.5, Simulations Plus Inc., US). Highest licensed drug dosage strengths were 
obtained from the European Medicines Agency (EMA) or Food and Drug Administration (FDA) 
databases. 
   
 
   
 
Biopharmaceutical Data Analysis  
Apparent drug solubility values in all media are presented as mean ± standard deviation (n=3) 
(Supplementary Materials). Solubility ratios (SR) for the 30 drugs with either FaSSIF-SEDDSMigylol812 
(referred to as SRMC) or FaSSIF-SEDDSOliveOil (referred to as SRLC) versus FaSSIF were calculated 
via Equation 1:  
(1) 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 𝑅𝑅𝑅𝑅𝑆𝑆𝑆𝑆𝑆𝑆 (𝑆𝑆𝑅𝑅) = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴𝑆𝑆 𝐹𝐹𝐴𝐴𝑆𝑆𝑆𝑆𝐹𝐹𝐹𝐹−𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝐴𝐴𝑆𝑆 𝐹𝐹𝐴𝐴𝑆𝑆𝑆𝑆𝐹𝐹𝐹𝐹
 
SR standard error (SE) was calculated from Equation 2 as previously reported (24): 
(2) SE = 𝑆𝑆𝑅𝑅 𝑥𝑥 �𝑆𝑆𝐴𝐴
2
𝐴𝐴2




Where A, B, SA and SB refer to the mean measured solubility values (24hrs) and standard errors for 
A (FaSSIF) and B (FaSSIF-SEDDS) respectively. In order to assess capacity for SEDDS to bridge the 
fasted-fed state solubility gap, SRMC and SRLC were related to comparative SRs for each drug using 
FeSSIF solubility in place of drug solubility upon SEDDS dispersion i.e. FeSSIF/FaSSIF. Graphs 
illustrating SRs were obtained using Prism (Version 5, Graphpad, USA). Linear regression was 
performed using Excel (Microsoft Office, 2016) to assess correlations between SR and individual drug 
properties or solubility in various media. To test significance between paired solubility values in 
FaSSIF-SEDDSMC versus FaSSIF-SEDDSLC the distribution of the difference was used to determine 
normality. A two sided bootstrap-paired test (5000 samples) was used to determine significance (p < 
0.05). A simple scatter plot was produced for FaSSIF-SEDDSMigylol812 versus FaSSIF-SEDDSOliveOil 
and regression coefficients fitted for interpretation and a bootstrap test for the coefficients conducted. 
A two sided independent samples t-test was used to analyse media droplet sizes and Levene’s test 
was used to check for equality of variances. A p-value < 0.05 indicated a violation of equal variance. 
All statistical analysis was conducted using SPSS Statistics (Version 26, IBM Corporation, US). 
Multivariate Data Analysis and Modelling Parameters 
Multivariate data analysis (MDA) was conducted using Unscrambler (Version 11, Camo Analytics, 
US). Molecular structures were acquired as smiles from PubChem and used as inputs for the ADMET 
Predictor software (Version 9.5, Simulations Plus, California, USA) to calculate >250 molecular 
descriptors. These were added to PSA and Tm and used as variable inputs for Principal Component 
Analysis (PCA) and Partial Least Squares (PLS) modelling. Modelling responses were the logarithm 
of SR in both SEDDS (logSRMC and logSRLC). PCA was first applied randomly to aid training/test set 
identification. A split of 70:30 (21:9 drugs) of training:test set was used to increase model robustness. 
Training set criteria was that it covered the test set chemical space along with a relatively even spread 
of SRs. Influential outliers were placed in the test set if they displayed both large residual and high 
leverage in the Influence plot. A Hotelling’s T2 ellipse was also applied for outlier detection (95% 
confidence interval).  
PLS was used to establish important descriptors for predicting SRMC and SRLC. The nonlinear 
iterative partial least squares (NIPALs) algorithm was utilised and all 250+ variables were mean 
   
 
   
 
centred, de-identified and standardized through scaling by standard deviation. Descriptors displaying 
the same value for all drugs were removed, along with skewed descriptors. To limit overfitting 
potential, a limit of two principal components was used. Variable reduction was performed to 
decrease complexity and noise. A Marten’s uncertainty test was applied to help identify important 
variables and assess stability. This involved a “jackknifing” procedure and production of sub-models to 
identify non-significant variables (34). Variable weighted beta coefficient rankings from the Important 
Variables plot and their p-values were also used to remove unimportant variables. Variables in the 
same area of the correlation loadings plot were removed leaving a singular variable. Variables near 
the centre of this plot were removed. Any change in r2 calibration and r2  validation was monitored. 
Model accuracy was validated by the Root Mean Square Error (RMSE) of validation and calibration. 
Models were validated by a full cross validation (leave-one-out) to improve power and by test sets of 
drugs not used in model development to strengthen general applicability. 
Solubility Equation for Predicting Biopharmaceutical Dose Number and DCS Class.  
It was then investigated if easily interpretable equations based on drug properties could predict SRMC 
and SRLC. Multiple linear regression (MLR) was performed using Excel (Microsoft Office, 2016) to 
investigate correlations between selected significant PLS model variables versus logSRMC and 
logSRLC. Equation development was monitored by descriptor p-values, the f-value, r2 and adjusted r2. 
The same training and test sets as PLS were used.  
DCS classification of each drug was obtained using solubility and permeability parameters outlined 
previously (22, 23). While drug permeability was predicted from the ADMET Predictor (Version 9.5, 
Simulations Plus Inc., US), solubility criteria was obtained using a dose/solubility ratio in 500mls of 
media using equation (3): 
(3) 𝐷𝐷𝑆𝑆 = 𝑆𝑆𝑆𝑆𝐷𝐷𝐴𝐴
(𝑆𝑆𝐷𝐷𝑆𝑆 )(𝑉𝑉𝐷𝐷𝑆𝑆)
 
Where, Dose is the highest dose, Ssi apparent solubility in biorelevant media i.e. FaSSIF, Vsi is the 
available fluid volume for dissolution in the small intestine (500 ml). 
Solubility criteria for DCS classification using experimentally determined solubility’s upon SEDDS 





Here, Cs is apparent drug solubility upon SEDDS dispersion in biorelevant media i.e. FaSSIF-
SEDDS.  
For DCS classifications using the predicted solubility ratios (SR) from the MLR equations, Cs(Predicted) 
was calculated using equation 5:  
(5) 𝐶𝐶𝐷𝐷(𝑃𝑃𝐴𝐴𝐴𝐴𝑃𝑃𝑆𝑆𝑃𝑃𝐴𝐴𝐴𝐴𝑃𝑃) = 𝑆𝑆𝑅𝑅 ∗ 𝑆𝑆𝐷𝐷𝑆𝑆  
   
 
   
 
Where SR is the predicted solubility ratio upon SEDDS dispersion from the MLR equations and Ssi is 
apparent solubility of the compound in biorelevant media i.e. FaSSIF. Incorporating equation 5, 






Predicting DCS Classifications of Commercial LBF Drugs  
To assess the equations’ general applicability to make predictions for drugs outside equation 
development and validation, Do(Predicted) was applied to a list of drugs that have been successfully 
commercialised as LBF products (4). DCS classifications were produced using Do(predicted) values 
(Equation 6), to predict if dose solubility limitations for the commercial drugs would be overcome upon 
SEDDS dispersion. FaSSIF solubility was obtained from literature or from the ADMET Predictor 9.5 
(Simulations Plus, USA) (Fagerberg et al., Fagerberg and Bergstrom, 2015). Predicted classifications 
were compared to classifications using FaSSIF solubility alone (Equation 3). 
 
  
   
 
   
 
Results 
SEDDS Characterisation on Biorelevant Dispersion  
SEDDSMigylol812 and SEDDSOliveOil both dispersed in FaSSIF and PhBpH6.5 to form uniform stable 
microemulsions with droplet sizes between 36-70 nm. PhB pH6.5-SEDDSMigylol812 and PhB pH6.5-
SEDDSOliveOil displayed significantly different mean droplet sizes (* p < 0.05) (Table 2). Droplet sizes 
of FaSSIF-SEDDSMigylol812 and FaSSIF-SEDDSOliveOil Ralso differed (* p < 0.05) and were smaller than 
PhBpH6.5-SEDDSMigylol812 and PhB pH6.5-SEDDSOliveOil. All PDI’s obtained were below 0.26 indicating 
droplet sizes on dispersion were moderately homogenous. In terms of charge, values close to zero 
mV were observed for PhBpH6.5-SEDDSMigylol812 and PhB pH6.5-SEDDSOliveOil as all SEDDS excipients 
were non-ionic and neutral. FaSSIF displayed an overall net negative charge (-14.67 mV), which 
remained, though reduced in magnitude, through dispersion of SEDDSOliveOil (-5.73 mV) and SEDDS 
Migylol812 (-5.35 mV) (Table 2). 
Solubility in Biorelevant SEDDS Dispersions – Comparison of SEDDS Migylol812 and SEDDS 
OliveOil  
For the 30 drugs, solubility in FaSSIF-SEDDSMigylol812 was higher than FaSSIF-SEDDSOliveOil as a 
paired bootstrap test revealed a significant difference in drug solubility between these medium chain 
and long chain lipid dispersions (* p < 0.05). Comparatively, the beta coefficient of the regression line 
for FaSSIF-SEDDSMigylol812 versus FaSSIF-SEDDSOliveOil was significant according to a bootstrap for 
coefficients test (* p < 0.05). A strong correlation was established between drug solubility in FaSSIF-
SEDDSMigylol812 and FaSSIF-SEDDSOliveOil (r2 0.97) (Figure 1), suggesting that for every 100 unit 
increase in FaSSIF-SEDDSOliveOil solubility units, FaSSIF-SEDDSMigylol812 increases on average by 
105.6 solubility units. Consequentially, this indicates that solubility determined in one lipid dispersion 
may be used to estimate solubility in the other.  
 
Solubility Ratio Trends 
Solubility ratios (SR) for 30 PWSDs upon dispersion of two SEDDS was experimentally determined 
(Figure 2), where SR >1 was seen in all cases, indicative of increased drug solubility on SEDDS 
dispersion in intestinal media. SRs ranged from 1.13 - 64.4 fold for SEDDSMigylol812 and from 1.04-59.7 
fold for SEDDSOliveOil. In presence of both SEDDS, Clotrimazole and Fenofibrate displayed the highest 
SRs. Trends in ionisable drugs were analysed. Cationic drugs appeared to consistently display high 
SR, with all such compounds displaying solubility gains of >2, with 3 and 2 drugs respectively 
displaying SR >10 fold in presence of SEDDSMigylol812 and SEDDSOliveOil. In contrast, solubility gains for 
anionic compounds appeared less pronounced, with 8/9 anionic drugs displayed SR <5. However, for 
Candesartan Cilexetil, a SR >16 was observed with both SEDDS. Candesartan Cilexetil is an 
ampholyte where the hydrogen attached to the O-CH(CH3)-O group in the cilexetil side chain is 
moderately acidic, being between the oxygen rich ester moieties, while also possessing a basic 
functional group. This ampholytic nature may have contributed to its deviation from the general trends 
observed for other anionic drugs. Neutral drugs displayed a wide range of SRs, while Celecoxib and 
Venetoclax deviated strongly from the trend of similar SRs in SEDDSMigylol812 and SEDDSOliveOil, with 
Celecoxib displaying a SRMC of 17 compared to a SRLC of 7, while Venetoclax also displayed a 
   
 
   
 
difference between SRMC and SRLC i.e. 12 versus 7. To assess SEDDS ability to mirror solubility 
increases in fed-state versus and fasted-state media, SRs obtained were compared to 
FeSSIF/FaSSIF solubility ratios. SRMC and SRLC exceeded SR FeSSIF/FaSSIF for 24 and 23 of the 30 
drugs respectively (Figure 3).  This observation confirms the utility of SEDDS as effective bio-enabling 
systems to bridge the fasted-fed state solubility gap (35).  
Computational Prediction of Biorelevant Solubility Gain with SEDDS.   
Linear Regression revealed weak correlations between both SRLC and SRMC versus individual drug 
properties. Lipophilicity and Tm, commonly utilised as guides towards LBF suitability, displayed poor 
quantitative relationships e.g. logP (r2 0.33, 0.32), logD6.5 (r2 0.43, 0.35) and Tm (r2 0.23, 0.25). 
Therefore, a combination of variables were required to improve quantitative prediction accuracy. 
Firstly, PCA verified the dataset structural diversity (Supplementary Materials). PLS model 
development resulted in predictive PLS models for both SRs (logSRMC and logSRLC). The PLS models 
used 1-2 principle components (PC) and 5-6 variables. The logSRMC 1 PC model produced 
predictions of r2 calibration 0.81, r2 validation 0.73 requiring 5 variables; logD6.5, melting point (Tm), 
molecular weight (MW), aromatic bonds as fraction of total bonds (F_AromB) and Atom-Type 
Cumulative Electrotopological State (E-state) index for methylene carbons (SssCH2). While the 
logSRLC 2 PC model required 6 variables; LogD6.5, MW, Tm, F_AromB, SssCH2 and number of 
aliphatic rings (N_AliphR) to produce predictions of r2 calibration 0.77, r2 validation 0.67. These 
models demonstrated good predictions of test sets, summarized in Table 3. 
Enhanced Biorelevant Solubility Ratio Equation  
As 5-6 descriptors could predict SRMC and SRLC, multiple linear regression was performed to produce 
easily interpretable predictive equations. All significant variables from PLS modelling were initially 
included in MLR. Insignificant variables (p > 0.05) from these initial equations were subsequently 
removed, resulting in final equations with higher F-values and significant variables. Two equations 
were produced (Table 3), both utilising 3 properties: logD6.5, Tm and F_AromB, Similarities between 
equations was expected due to the high correlation between dispersed SEDDS (Figure 1). 
Use of Predicted Solubility Ratios to Predict Drug DCS Class with SEDDS.  
Application of the equations to predict drug DCS class with SEDDS was assessed and accuracy 
compared to comparative DCS classifications using experimentally determined solubility’s upon 
SEDDS dispersion. DCS Permeability classifications were estimated using drug permeability 
predictions from the ADMET Predictor 9.5 (Simulations Plus, USA).  While use of a computationally 
derived permeability estimate has been applied in other studies (36), it must be acknowledged that 
drug specific effects may not be adequately captured in these predicted permeability estimates. In 
total, using experimental solubility’s, 10 drugs overcame a solubility limitation i.e. transitioned to DCS 
Class I/III. Using the Do(Predicted) approach (Equation 6), this transition was correctly predicted for 8/10 
drugs (Table 4) i.e. Clotrimazole, Cinnarizine, Fenofibrate, Isotretinoin, Naproxen, Terfenadine, 
Glipizide and Venetoclax. DCS Classification using Do(SEDDS)  (Equation 4) also resulted in transitions 
to “good solubility” for Candesartan Cilexetil and Celecoxib (SEDDSMigylol812 only), however, as 
previously discussed experimental results for both drugs differed significantly from general trends 
   
 
   
 
observed, which may suggest a drug specific effects in these cases that was not captured in the MLR 
equations. 
Predicted DCS Classifications of Commercial LBF Drugs.  
The utility of the Do(Predicted) approach to guide a LBF formulation strategy was subsequently assessed 
by applying the MLR equations to a range of drugs that have been successfully licensed as LBFs. A 
total of 49 drugs were selected initially, and the DCS classification using FaSSIF solubility alone was 
employed to determine DCS class. In total, 23 drugs were initially classified as DCS class I/III, and 
therefore, did not display solubility limitations. These compounds were therefore excluded from further 
analysis as a bio-enabling strategy was not considered necessary. Applying the Do(Predicted) approach 
to the remaining 26 drugs, 10 drugs were predicted to transition from poor to good solubility, and a 
further 7 drugs were found to transition from DCS Class IIb to Class IIa i.e “dissolution rate limited” 
which can offer delivery opportunities, where the compensatory influence of high permeability has 
been stated to be significant for acceptable oral absorption during the transit time in the intestine (22). 
Therefore, this approach predicted that in 65.4% (i.e. 17/26) of drugs, a SEDDS approach was likely 
to overcome solubility limited absorption. Of the 9 drugs that remained in poor solubility classification 
after applying the Do(Predicted) approach, 8 were DCS Class IV, which may indicate that decisions to 
employ a SEDDS approach were not solely influenced by solubility considerations and that other 
factors, such as increased permeability, may have been a consideration in the choice to develop as a 
LBF (Table 5).  
Discussion 
Over the last two decades, significant strides have been made in applying computational approaches 
across the full spectrum of drug development (37). In their many forms, computational tools can 
include discovering new lead candidates with optimal drug-receptor binding affinity (e.g. Quantitative 
Structural Activity Relationships (QSAR)), to guiding on optimal physiochemical profiles (e.g. 
Quantitative Structural Property Relationships (QSPR)) or predictions of biopharmaceutical properties 
including solubility and permeability (9). While the major advances in the use of computational tools 
to-date have been focused on chemical structural design to assist the selection of new drug 
substances with optimal pharmacodynamic and/or pharmacokinetic properties, commonly referred to 
as “druggability”, more recently, the use of computational tools to guide on formulation design, or 
computational pharmaceutics, have been reported (9, 38, 39). These include approaches such as 
computational biopharmaceutical drug profiling, recently reported as an approach to predict 
physiochemical and molecular properties of drug candidates that render them more or less suitable 
for formulation via a specific bio-enabling formulation approach (9). Accordingly, there exists an 
increasing focus on development of reliable computational pharmaceutics tools, capable of guiding 
selection of appropriate bio-enabling formulation strategies, in particular for drug candidates which 
display either solubility and/or permeability limitations.  
LBFs are one such bio-enabling formulation technology that exploit the benefit of lipid excipients to 
harness the absorption pathways of dietary fats, leading to increased intestinal drug solubility and 
   
 
   
 
improving intestinal absorption. The benefits of lipid excipients to increase drug solubility were clearly 
prevalent in this study, where increased solubility was observed for all 30 PWSDs following dispersion 
of the SEDDS in biorelevant media. Indeed, the solubility increases observed were on average higher 
than the fed:fasted biorelevant solubility ratio, as SRMC and SRLC exceeded SR FeSSIF/FaSSIF for 24 and 
23 of the 30 drugs respectively (Figure 3). However, despite clear benefits as a bio-enabling 
technology, it is generally considered that LBFs have an unfulfilled potential in a commercial sense. 
Over the last decade, prevalence of commercial LBFs appears to be decreasing relative to Solid 
Dispersions (SD) (4), reflecting improved scientific knowledge on the pharmaceutical benefits of SDs 
in terms of bio-enabling effects (e.g. increased drug solubility), but also an improved understanding of 
factors influencing industrial scalability and regulatory approval (e.g. long term stability). On the other 
hand, the prevalence of commercial LBFs has tended to be relatively few, reflecting gaps in 
understanding both in terms of bio-enabling benefits and from an industrial perspective, as recently 
reviewed (5).  With this in mind, significant strides have been made in the use of in silico approaches 
to reliably predict dose loading capacity in LBFs (11, 12). This current study sought to advance the 
application of computational pharmaceutics tools to consider the impact of in vivo dispersion of 
SEDDS on drug solubility in GI fluids. In recognition of the importance of in vivo dispersion on SEDDS 
performance (40), we hypothesised that computational prediction of drug solubility increases seen 
upon dispersion of SEDDS in simulated biorelevant fluids is likely to be a key performance indicator of 
whether a SEDDS approach can effectively solubilise the dose in vivo. As such, a computationally 
predicted solubility ratio (SR), based on drug properties in combination with experimentally 
determined solubility in FaSSIF, would support more informed decisions on formulation options in 
early development, by allowing estimation of a biopharmaceutically relevant Do.  
Resultantly, our hypothesis that a relationship could be elucidated between a biorelevant SR for a 
SEDDS formulation and drug properties was demonstrated and shown to be robust. We observed, on 
a dataset of 30 PWSDs using PLS computational modelling, that 5-6 drug properties were sufficient to 
reliably predict SR upon dispersion of two prototype SEDDS (logSRMC r2  0.81, logSRLC r2 0.77). 
Subsequently, employment of MLR facilitated simplified equations for SR to be generated, requiring 
only 3 drug properties namely, partition coefficient pH 6.5 (logD6.5), melting point (Tm) and aromatic 
bonds as fraction of total bonds (FArom_B). These represent common drug properties typically 
identified and integrated into an early stage pharmaceutical drug profiling environment (10), forgoing 
requirements for molecular fragment profiling or specialised chemometric software.  
Inclusion of drug properties in this computational model, implies their importance to SR upon SEDDS 
dispersion at a mechanistic level. For the logSRMC model, important descriptors were LogD6.5, Tm, 
MW, F_AromB and SssCH2. Additionally, the logSRLC model also included N_AlipR. In terms of, 
logD6.5, Tm and MW, these are widely recognised drug properties from a pharmaceutical profiling 
context. In both PLS models, logD6.5 and MW were positively correlated with SR while Tm was 
negatively correlated. Inclusion of a partition coefficient descriptor was not unexpected due to addition 
of lipophilic SEDDS to the media, while logD6.5  was previously observed to be strongly correlated with 
PWSD solubilisation in biorelevant media (25), and an influential descriptor in modelling the 
   
 
   
 
FaSSIF/PhBpH6.5 ratio (24). Additionally, distribution coefficient has been used to characterise drug 
release from SEDDS, or more specifically the drug diffusion process from the SEDDS pre-concentrate 
into aqueous media has been related to logDSEDDS/RM i.e. the distribution coefficient of solubility in 
SEDDS pre-concentrate and the release medium (41). Conversely, the negative correlation between 
Tm and SR is most likely attributable to high Tm molecules exhibiting solid state limited solubility or 
‘brick dust’ drugs, which results in poor solubility in lipid excipients, translating to more modest SR 
values upon SEDDS dispersion. While the importance of MW as a descriptor is not unexpected given 
the influence of MW on both crystalline structure characteristics and solvation properties, in contrast 
to trends observed between MW and aqueous solubility (42), MW and SR in this case are positively 
correlated. Accordingly, as increasing size negatively influences aqueous solubility, MW may be 
indirectly conveying information regarding relative drug affinity for lipophilic formulation excipients to 
that for the comparatively more aqueous environment within the biorelevant medium. Finally, a recent 
retrospective analysis of selected physiochemical and molecular properties of drugs produced 
commercially as LBF products versus commercial SD drugs and a database of drugs not produced 
via either bio-enabling approach, found logD, Tm and MW to be significant descriptors signally 
commercial success with LBFs. Similar to this study, increasing logD and MW were found to be 
significant for LBF commercial success, while a lower relative drug Tm was found to be significant to 
reach commercialisation (4). The fact that these descriptors were significant in both a retrospective 
analysis of successfully commercialised LBFs and in this prospective SR prediction upon SEDDS 
dispersion, re-emphasises their importance as contributing factors to drug-LBF technology success 
and suitability.  
Additionally, SssCH2, F_AromB and N_AlipR were significant in PLS modelling. F_AromB was 
positively correlated to SR. While this positive correlation is in contrast to previous predictions of HIF 
solubility (28), it is likely that as increasing aromatic ring count decreases aqueous solubility (43, 44), 
and an increase in affinity for lipid excipients is seen. In this case, compounds with larger aromatic 
structures are likely to have a negative influence on aqueous solubility. Upon SEDDS dispersion, 
such compounds will associate with greater affinity to the lipid rich microemulsions droplets formed, 
resulting in a higher SR. However, contributions of aromaticity are likely complex, reliant on numerous 
factors including; attached substituents and their polarity, existence of ‘through resonance’ with 
attached substituents, as well as ion-dipole and dipole-dipole interactions with other moieties. Number 
of aromatic bonds was previously significant for in silico prediction of FeSSIF/FeSSIF blank buffer, 
further highlighting the significance of aromaticity for solubility in media with increasing lipids (25). 
N_AlipR also influences drug shape and size and is also affected by adjacent moieties. Meanwhile, 
SssCH2 examines the topological and electronic features of a structure (45) and was previously 
significant in an in silico prediction of solubility in FaSSIF buffer (25).  
This work also investigated other factors influencing SR in order to understand of how drugs 
associate with biorelevant SEDDS dispersions. In terms of drug ionisation, general trends of higher 
SR for cationic (charged basic) versus anionic (charged acidic) drugs were observed. This 
observations are in line with previous research where solubility increases in biorelevant media versus 
   
 
   
 
corresponding blank buffers for bases and neutral drugs were higher than acids (25). Such increases 
for cationic drugs, have previously been suggested to stem from favourable electrostatic interactions 
between negatively charged polar head groups of taurocholate bile salts (46, 47) and positively 
charged drugs. In this case, such bile salt related electrostatic interactions are likely to occur in both 
FaSSIF and FaSSIF-SEDDS, with net negative charges observed for all three media. The general 
trend for increased SR for cationic compounds occurred despite an overall reduction in net negative 
charge in both FaSSIF-SEDDS media relative to FaSSIF, demonstrating the possibility that additional 
electrostatic interactions may exist. As both alterations to droplet sizes and to overall charge of the 
media upon SEDDS dispersion in FaSSIF versus PhBpH6.5 were observed, interactions between the 
SEDDS and biorelevant solubilising components of FaSSIF are probable. In particular, the negative 
charges of FaSSIF-SEDDSMigylol812 (-5.35 mV) and FaSSIF-SEDDSOliveOil (-5.73 mV), were 
intermediate of the overall charges of FaSSIF (-14.67 mV) and the values close to zero observed 
upon SEDDS dispersion in PhBpH6.5 (-0.76 mV, -1.27 mV), suggesting surface association of charged 
bile salts to the oil droplets formed upon SEDDS dispersion. Such an association was previously 
proposed upon initial in vitro dispersion of a SEDDS in a biorelevant media (48). It therefore could be 
suggested upon SEDDS dispersion, favourable interactions between cationic drugs and these 
charged bile salts found at the oil droplet surface may help explain the increased SRs observed. 
Previously, electrostatic interactions between cationic drugs and free fatty acids in post digestive 
media have also been suggested as a potential mechanism for increased drug solubilisation.(40). 
However, presently such interactions are poorly understood and electrostatic interactions appear to 
not be the sole solubilising mechanism involved, given that both neutral and cationic drugs also 
displayed SRs between 1.1 and 51, hence indicating that there are a number of additional factors 
governing drug associated with mixed colloidal dispersion.  
In terms of excipient effects, SEDDSMigylol812 and SEDDSOliveOil were compared. A strong correlation 
was observed between solubility in FaSSIF-SEDDSMigylol812 versus FaSSIF-SEDDSOliveOil, suggesting 
that strong correlations previously observed between drug solubility in MCT versus LCT 
preconcentrates, and C8 versus C10 triglycerides are also observed upon SEDDS dispersion of these 
exemplary MCTs and LCTs (11, 15). In all cases solubility in FaSSIF-SEDDSMigylol812 was higher than 
FaSSIF-SEDDSOliveOil, with an overall significant difference observed (* p < 0.05). However, the extent 
of solubility difference between both was relatively small i.e. for 20 out of the 30 drugs the difference 
was < 20 %. Therefore, in terms of the choice of these exemplary MCT or LCT containing SEDDS, 
the practical implications in terms of solubility difference on dispersion in biorelevant buffer appear 
relatively minor. The merits of MCT versus LCT have been widely discussed (49, 50). While in 
general, drug solubility in most examples of MCTs is higher (1, 51), following formulation digestion, 
the digestion products of LCT may confer additional advantages (52), while it must also be 
acknowledged that these trends may not be observed for all MCT and LCTs comparisons. This study 
also identified two specific drug examples, namely Celecoxib and Venetoclax, where large differences 
in SR were observed, relating to large solubility percentage differences (58% and 43%) being 
observed between both SEDDS dispersions. The possible reason for these higher associations with 
dispersed SEDDSMigylol812 for these two neutral drugs are unclear, however this highlights a potential 
   
 
   
 
limitation of computational predictions to capture specific drug-excipient solubility effects. Therefore, 
future work with a wider range of drugs could help to increase robustness of the predictions achieved.  
Overall, this work endeavoured to advance the field of computational pharmaceutics by demonstrating 
the capacity for such predictive tools to inform developability, and specifically to guide formulation 
decisions regarding SEDDS by assessing their ability to improve the biopharmaceutical dose number. 
Do(Predicted) (Equation 6) can be easily applied as a computational pharmaceutics tool to guide 
formulation suitability, requiring only 3 readily obtainable drug properties, in addition to an 
experimentally determined drug solubility in FaSSIF. The suitability of Do(Predicted) to forecast 
developability was validated by comparing predicted to experimental Do values, showing that 8/10 
drugs were correctly predicted to transition to a “good solubility” DCS class (I/III). The two drugs, 
Candesartan Cilexetil and Celecoxib that were not predicted to transition most likely reflect the 
limitation of the model to capture drug specific solubility increases, as discussed previously. 
Subsequently, to demonstrate the real-time applicability of such predictions in a pharmaceutical 
developability context, Do(Predicted) was applied to a drug dataset outside the training and test sets, 
namely drugs previously successfully produced as commercial LBF products. The Do(Predicted) 
approach predicted that two out of three (65.4%) of these drugs would offer benefits for development 
as a LBF. Furthermore, when DCS classes using FaSSIF solubility versus DCS class using predicted 
solubility with SEDDS were compared, 8 of the 9 commercial drugs which demonstrated no class 
transition were DCS Class IV. Therefore, as these predictions are based upon drug solubility gains 
with SEDDS it is likely that permeability considerations, not only solubility benefits, were influential in 
the development of these poorly soluble and poorly permeable drugs with LBFs.  
Comparable to the stated limitation of the original DCS classification system (22), potential for 
supersaturation was not explored in these predictions. This would have particular relevance for 
ionisable drugs displaying pH dependent solubility, while weakly basic drugs in particular exhibit 
higher solubility in gastric media, along with potential for intestinal supersaturation and precipitation. 
Further limitations of the predictions are also acknowledged in terms of the deliberate omission of 
exploration of the effect of SEDDS digestion on drug solubility. We therefore acknowledge that this 
tool is conservative in its approach to solubility predictions and the solubility gains are likely to be 
under predictive of the kinetic solubility’s achieved in the gastrointestinal tract. However, from an 
industry perspective, where conservative risk:benefit approaches are often applied to formulation 
development, this low risk approach may be in line with current industrial preferences. To overcome 
any conservative nature in the application of a predicted Do, we suggest incorporation of this tool into 
the refined Developability Classification System (rDCS) as part of the initial “standardised 
investigations” (23). For a weakly basic drug, customised investigations such as the small-scale 
supersaturation/precipitation experiments as specified in the rDCS could be then triggered to test the 
potential effects of supersaturation.  
 
   
 
   
 
Conclusion 
Through combinations of in silico predictions based on drug properties, and drug solubility screening 
in FaSSIF, this work demonstrated capacity for computational pharmaceutics to inform drug 
developability. By applying a computational pharmaceutics approach this study identified drug 
properties that can be used to predict SR for SEDDS dispersions. The results demonstrated that 
integration of biorelevant experimentally determined FaSSIF solubility into computationally predicted 
dose numbers (i.e. combining molecular, physiochemical and biopharmaceutical properties), allows 
more reliable biopharmaceutically relevant and data-driven decisions to be made on drug-SEDDS 
developability. While it is acknowledged that in silico predictions are not intended to completely 
circumvent experimental solubility screening, when used in conjunction with appropriate screening 
assays, such tools can guide likely successful bio-enabling approaches in a biopharmaceutically 
informed manner. In order to advance this growing field of computational pharmaceutics for LBFs, 
renewed emphasis should be placed upon creating validated and increasingly robust computational 
predictions of drug developability with bio-enabling formulations.  
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Table 1: Selection of Physiochemical and Molecular Properties of Investigated Compounds collated from literature or ADMET Predictor 9.5. 0 = no charge at pH 6.5, + = 
positive charge, - = negative charge.  Am = Ampholyte. % refers to the percentage of the drug’s ionisable groups ionised at pH 6.5 according to the Henderson-Hasselbalch 
Equation.  
Drug Compound MW (g/mol) clogP logD6.5 Acid/Base 
 /Neutral 
pKa (% ionised 
at pH 6.5) 
Classification of 













































































































































































4.12 (0%), 7.4 (11%) 
4 (99%) 
3.7 (0%) 





























































































































































































































   
 
   
 
Table 2:  
 
 
Table 2: Size determination and ζ-potential of the media used in the course of the analysis demonstrating that 




















Figure 1: Scatter plot of Solubility in FaSSIF-SEDDSMigylol812 versus Solubility in FaSSIF-SEDDSOliveOil displaying 



























   
 
























Figure 2: SR (drug solubility in dispersed SEDDS media/FaSSIF) achieved for Neutral, Cationic and Anionic 
Drugs (pH 6.5). Higher SRs are seen in general for Cationic and Neutral drugs versus Anionic drugs where every 









   
 
































Figure 3: SR (drug solubility in both dispersed SEDDS media/FaSSIF and FeSSIF/FaSSIF). FeSSIF/FaSSIF SR 
is overcome with SEDDSMC for 24 drugs and with SEDDSLC for 23 drugs, demonstrating ability of the SEDDS to 











   
 


















































RMSEP Cross Validation 
 





























RMSEP Cross Validation 
 





















MLR  Equations 
 

























































=  0.6 +  0.2(𝑆𝑆𝑆𝑆𝑙𝑙𝐷𝐷6.5)  
+  1.02(𝐹𝐹_𝐴𝐴𝐴𝐴𝑆𝑆𝐴𝐴𝐴𝐴) –  0.01(𝑇𝑇𝑚𝑚) 
 
𝑆𝑆𝑆𝑆𝑙𝑙𝑆𝑆𝑅𝑅𝐿𝐿𝐶𝐶
=  0.54 +  0.17(𝑆𝑆𝑆𝑆𝑙𝑙𝐷𝐷6.5)      




Table 3: Overview of the PLS models and MLR equations produced for SRMC and SRLC based on drug 
descriptors. Tr = Training Set, Te = Test Set. Where calibration refers to the training set and validation refers to 
the test set. RMSE = Root Mean Square Error. RMSEC = Root Mean Square Error of Calibration. RMSEP = Root 








   
 
   
 
 
 FaSSIF  SEDDSMigylol812 SEDDSMigylol812 SEDDSOliveOil SEDDSOliveOil  




DCS Class DCS Class DCS Class DCS Class  
Albendazole IIb IIb IIb IIb IIb  
Candesartan Cilexetil IV III IV III IV IV → III 
Carbamezapine IIa IIa IIa IIa I  
Carvedilol I I I I I  
Celecoxib IIb I IIb IIa IIb IIb → IIa/I 
Cinnarizine IIa I I I I IIa → I 
Clofazimine IIb IIa IIa IIa IIa IIb → IIa 
Clotrimazole IIa I I I I IIa → I 
Danazol IIa/IIb IIa IIa IIb IIa  
Dipyridamole IV IV IV IV IV  
Felodipine I I I I I  
Fenofibrate IIb I I I I IIb → I 
Glipizide IV III III III III IV → III 
Griseofulvin IIb IIb IIb IIb IIb  
Haloperidol I I I I I  
Indomethacin I I I I I  
Irbesartan IV IV IV IV IV  
Isotretinoin IIa I I I I IIa → I 
Itraconazole IIb IIb IIb IIb IIb  
Ketoconazole IIb IIb IIa/IIb IIb IIb  
Mefenamic Acid IIb IIa IIa/IIb IIa IIb  
Naproxen IIa I I I I IIa → I 
Nifedipine IIb IIa IIa/IIb IIa IIa/IIb IIb → IIa 
Phenytoin IIb IIb IIb IIb IIb  
Progesterone IIb IIa IIa IIa IIa IIb → IIa 
Spironolactone IIa/IIb IIa IIa IIa IIa  
Tamoxifen I I I I I  
Terfenadine IIa I I I I IIa → I 
Tolfenamic Acid IIa IIa IIa IIa IIa  




Table 4: DCS classification of the 30 drugs using both experimental and predicted solubility values. DCS Classes 
are shown using FaSSIF solubility and both experimentally and predicted solubility’s upon SEDDSMigylol812 and 




   
 




FaSSIF  SEDDSMigylol812  SEDDSOliveOil  
 
 
Do Equation Used Do Do(Predicted) Do(Predicted) DCS Class 
Transition 
 
Drug DCS Class DCS Class DCS Class 
 
 
Clomethiazole Edisilate IIa I I IIa → I  
Dronabinol IIa I I IIa → I  
Ergocalciferol IIa I I IIa → I  
Isotretinoin IIa I I IIa → I  
Cholecalciferol IIb I I IIb → I  
Clofazimine IIb IIa IIa IIb → IIa  
Efavirenz IIb I IIa IIb → I/IIa  
Enzalutamide IIb IIa IIa IIb → IIa  
Ethyl Eicosapentaenoate IIb IIa IIb IIb → IIa  
Fenofibrate IIb I I IIb → I  
Loratidine IIb IIa IIa IIb → IIa  
Menatetrenone IIb IIa IIa IIb → IIa  
Nimodipine IIb I IIa IIb → I/IIa  
Progesterone IIb IIa IIa IIb → IIa  
Teprenone IIb IIa IIa IIb → IIa  
Tocopherol Nicotinate IIb I IIa IIb → I/IIa  
Amprenavir IV III III IV → III  
Nintedanib IIb IIb IIb 
 
 
Azithromycin IV IV IV 
 
 
Ciprofloxacin IV IV IV 
 
 
Cyclosporin A IV IV IV 
 
 
Lopinavir IV IV IV 
 
 
Ritonavir IV IV IV 
 
 
Saquinavir IV IV IV 
 
 
Tipranavir IV IV IV 
 
 





Table 5: DCS Classification of commercial LBF drugs which displayed dose solubility limitation in FaSSIF (Class 
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1. Apparent solubility values in PhBPh6.5, FaSSIF, FeSSIF, FaSSIF-SEDDSMigyolo812, FaSSIF-SEDDSOliveOil, and SR for SEDDSMigylol812, SEDDSOliveOil, and FeSSIF 
versus FaSSIF. FE = Food Effect.  
 
Drug Compound PhBpH6.5 ± SD 
 
(µg/mL) 
FaSSIF ± SD 
 
(µg/mL) 










































0.9 ± 0.4 
- 





2.3 ± 0.3 
0.3 ± 0.05 
6.35 
1.187 
0.3 ± 0.0 
22.5 ± 0.6 
15 
77.81 
219.0 ± 78.0 











13.6 ± 1.3 
27.404 
0.04 
1.9 ± 0.0 
8.26 
266.1 ± 31.4 
55.9 
34.09 ± 5.12 
13.4 
6.2 





31.3 ± 3.3 
20 ±0.9 
110.51 
443.0 ± 10.0 
112.0 ± 3.4 
52.21 
0.33 








89.0 ± 4.0 
62.779 
20.729 ±0.51 
6.1 ± 0.1 
10 
524.1 ± 25.0 
305.0 ± 2.0 
226 
112 ± 2.0 
29.6 
71.1 ± 6.0 
28.8 ± 0.4 
137.2 ± 6.2 
237.0 ± 1.0 
40.4 ± 2.9 
4.3 ± 0.2 
29.2 ± 3.4 
120.9 ± 7.3 




403.3 ± 16.5 
649 
401 
46.1 ± 1.0 
283 
78.6 ± 16.2 
46.0 ± 2.5 
236.0 ± 13.0 
256 
41.0 ± 0.5 
28.4 ± 2.2 
9.62 ± 1.28 
138.9 ± 9.6 
388.127 ± 13.46 
634.098 ± 5.46 
579.82 ± 33.83 
228.9 ± 10.84 
57.8 ± 1.68 
225.43 ± 17.8 
59.09 ± 1.44 
42.90 ± 1.19 
337.47 ± 29.1 
482.39 ± 47.175 
35.47 ± 0.62 
37.35 ± 0.8675 
347.44 ± 25.48 
811.48 ± 9.1 
306.29 ± 31.19 
188.3 ±6 .90 
4.763 ± 0.16 
109.32 ± 5.65 
212.46 ± 13.292 
2356.17 ± 95.78 
124.78 ± 9.93 
61.51 ± 7.24 
89.34 ± 5.98 
61.9  ±7.08 
1081.47 ± 56.36 
371.23 ± 15.46 
311.56 ± 16.03 
246.340 ± 25.75 
7.44 ± 1.634 
138.49 ± 4.63 
379.83 ± 16.47 
442.88 ± 32.49 
240.02 ± 16.07 
194.05 ± 9.45 
47.12 ± 4.24 
208.95 ± 11.27 
41.61  ± 3.79 
37.873 ± 0.907 
245.36 ± 14.63 
286.55 ± 26.29 
32.523 ± 1.27 
34.15 ± 0.57 
243.65 ± 14.83 
794.21 ± 4.77 
277.5 ± 37.22 
155.53 ± 6.30 
2.89 ± 0.5 
98.21 ± 7.43 
198.6 ± 13.19 
2255.05 ± 75.76 
101.72 ± 9.65 
56.29 ± 5.58 
62.72 ± 1.21 
47.8 ± 6.05 
882.21 ± 20.79 
329.95 ± 4.28 
224.37 ± 7.13 




























































































   
 
   
 
2. RP-HPLC/UV methods for the 6 drugs completed using the Shake Flask Method with HPLC-UV analysis.  
Drug  Column A B Ratio Temp (°C) Flow Rate 
(ml/min) 
Inj. Vol (µL) λ (nm) 
Danazol Symmetry C18 5 µm, 4,6 x 150 mm  ACN Water 55:45 25 1 50 286 
Ketoconazole Symmetry C18 5 µm, 4,6 x 150 mm  Phosphate 




40:60 25 0.8 50 297 
Venetoclax Zorbax Eclipse Plus-C18 column (5 μm, 4.6 
mm x 150 mm) including Zorbax 156 Eclipse 
Plus-C18 guard column (5 μm, 4.6 mm x 
12.5 mm) 
ACN + 0.5 % TFA  Water + 0.5 
% TFA 
53:47 40 1 50 316 
 Fenofibrate Symmetry C18 5 µm, 4,6 x 150 mm  NaAc 25 mM, 
pH 5.0 
 
ACN 20:80 25 1 50 287 
Celecoxib Symmetry C18 5 µm, 4,6 x 150 mm  ACN + 
0,15%TEA, pH3 
Water  55:45 25 1 20 254 












   
 
   
 
3. Principle Component Analysis (PCA) scores plot detailing the chemical space occupied by 
the Training and Test Sets of the dataset.  
 
61% of the variation in the dataset is explained by PC-1 and PC-2 and Venetoclax is outside the 





4. Preliminary Studies Testing the Two Solubility Methods Used.  
Drug Solubility in FaSSIF-SEDDSMigylol812 and FaSSIF-SEDDSOliveOil completed for both shake flask and 
µDISS methods using Danazol. Solubility’s were obtained using FaSSIF-V2 for the µDISS method, 
which contains a smaller concentration of lecithin, due to powder availability at that time, therefore 
a ratio of solubility in MC/LC was calculated to test similarity of results instead of direct comparisons. 
Results:  
 Shake Flask  uDiss Ratio MC/LC 
Solubility 
FaSSIF-SEDDSMigylol812 59.089 µg/mL (±1.44) 37.130 µg/mL (±0.589) Shake Flask = 1.42 
FaSSIF-SEDDSOliveOil 41.612 µg/mL (± 3.79). 22.878 µg/mL (±1.138) µDISS = 1.6 
 
 
